Sugi Predict

Sugi Predict / Compounds / SCHEMBL21458099

SCHEMBL21458099

SCHEMBL21458099

CC(N)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=S)[nH]c1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PYGM P11217 3/20 0.52
▸ SLC28A1 O00337 1/20 0.46
▸ SLC28A2 O43868 1/20 0.46
▸ SLC29A1 Q99808 1/20 0.46
▸ SLC28A3 Q9HAS3 1/20 0.46
▸ TK2 O00142 2/20 0.46
▸ P2RY2 P41231 1/20 0.45
▸ CDK1 P06493 1/20 0.42
▸ LMNA P02545 2/20 0.42
▸ MTOR P42345 2/20 0.42
▸ THRB P10828 1/20 0.42
▸ MDM2 Q00987 1/20 0.42
▸ NCOA1 Q15788 1/20 0.42
▸ NCOA3 Q9Y6Q9 1/20 0.42
▸ GMNN O75496 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ NFKB1 P19838 1/20 0.42
▸ DNMT1 P26358 1/20 0.42
▸ THPO P40225 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6829043 0.88 PYGM (0.63) PYGMSLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL27965304 0.88 PYGM (0.49) PYGMSLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL5145484 0.88 PYGM (0.49) PYGMSLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL27760732 0.88 PYGM (0.51) PYGMSLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL1932437 0.87 PYGM (0.50) PYGMSLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL28344680 0.87 PYGM (0.50) PYGMSLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL20550037 0.86 PYGM (0.49) PYGMSLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL20534354 0.85 PYGM (0.48) PYGMSLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL441977 0.85 PYGM (0.48) PYGMSLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL29002253 0.84 PYGM (0.46) PYGMSLC28A1SLC28A2SLC29A1SLC28A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118161602-A RNA for treating autoimmune diseases 生物技术公司 2024-06-11 — — CN claimed
US-12220485-B2 Method of making lipid-encapsulated RNA nanoparticles ARCTURUS THERAPEUTICS, INC. (US) 2025-02-11 — — US disclosed
US-12037616-B2 Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions CRISPR THERAPEUTICS AG (CH) 2024-07-16 — — US disclosed
CN-118161602-A RNA for treating autoimmune diseases 生物技术公司 2024-06-11 — — CN disclosed
WO-2024118866-A1 GPC3-SPECIFIC ANTIBODIES, BINDING DOMAINS, AND RELATED PROTEINS AND USES THEREOF MODERNATX, INC. (US) 2024-06-06 — — WO disclosed
US-11883534-B2 Immunisation with lipid formulations with RNA encoding immunogens GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-01-30 — — US disclosed
WO-2024006978-A2 IMPROVED METHODS FOR IN VITRO TRANSCRIPTION ARCTURUS THERAPEUTICS, INC. (US) 2024-01-04 — — WO disclosed
US-20230398076-A1 METHOD OF MAKING LIPID-ENCAPSULATED RNA NANOPARTICLES ARCTURUS THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-20230242899-A1 METHODS AND COMPOSITIONS FOR MODULATING A GENOME TESSERA THERAPEUTICS, INC. 2023-08-03 — — US disclosed
US-11690864-B2 Delivery of RNA to trigger multiple immune pathways GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-07-04 — — US disclosed
EP-4114413-A1 COMPOSITE RNA PARTICLES BioNTech SE (DE) 2023-01-11 — — EP disclosed
US-10907161-B2 Synthetic RIG-I-like receptor agonists CHECKMATE PHARMACEUTICALS, INC. (US) 2021-02-02 — — US disclosed
US-20200063141-A1 SYNTHETIC RIG-I-LIKE RECEPTOR AGONISTS CHECKMATE PHARMACEUTICALS, INC. 2020-02-27 — — US disclosed
US-20190351040-A1 RNA CANCER VACCINES MODERNATX, INC. (US) 2019-11-21 — — US disclosed
US-20190321464-A1 HUMAN CYTOMEGALOVIRUS RNA VACCINES MODERNATX, INC. (US) 2019-10-24 — — US disclosed
US-20190314493-A1 HUMAN CYTOMEGALOVIRUS VACCINE MODERNATX, INC. (US) 2019-10-17 — — US disclosed
CN-104105504-A Recombinant polycistronic nucleic acid molecules NOVARTIS AG 2014-10-15 — — CN disclosed
CN-103269713-A Antigen delivery platforms NOVARTIS AG 2013-08-28 — — CN disclosed
CN-103153284-A Liposomes containing lipids with pKa values that facilitate RNA delivery NOVARTIS AG 2013-06-12 — — CN disclosed
CN-101060864-A Delivery of polynucleotides ANESIVA INC (US) 2007-10-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230398076-A1 METHOD OF MAKING LIPID-ENCAPSULATED RNA NANOPARTICLES AUP1, RNGTT, LIPC PYGM 4854/4885SLC28A1 2741/4885SLC28A2 3307/4885
US-20190314493-A1 HUMAN CYTOMEGALOVIRUS VACCINE NSUN2, NSUN3, RNMT PYGM 3302/4885SLC28A1 3167/4885SLC28A2 3285/4885
US-20190321464-A1 HUMAN CYTOMEGALOVIRUS RNA VACCINES NSUN2, NSUN3, SNRPA PYGM 3493/4885SLC28A1 2686/4885SLC28A2 2907/4885
US-11883534-B2 Immunisation with lipid formulations with RNA encoding immunogens STING1, CGAS, RNMT PYGM 4412/4885SLC28A1 2420/4885SLC28A2 2993/4885
US-20190351040-A1 RNA CANCER VACCINES TP53, KRAS, STING1 PYGM 1955/4885SLC28A1 4138/4885SLC28A2 4205/4885
US-12220485-B2 Method of making lipid-encapsulated RNA nanoparticles AUP1, RNGTT, LIPC PYGM 4854/4885SLC28A1 2741/4885SLC28A2 3307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.